Lung CancerNCT07720141
Dissemination Of Lung Cancer Screening Education Through Tobacco Quitlines
A study testing High-touch strategy in people with Lung Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
The goal of this research study is to compare two different ways to increase lung cancer screening rates for tobacco quitline clients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer
- What is being tested?
- High-touch strategy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 650 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2027to 30 Jun 2034
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Quitline Client
- Quitline client participants must meet the criteria for LCS with regards to age (50 to 80 years) and smoking history (20+ pack-years). This project will not re-confirm quitline client participant eligibility for screening. Tobacco treatment specialists will elicit study interest from only eligible quitline clients.
- Representative of the Quitline Community
- Representative of the Quitline Community will include any employee of the quitline service provider, representative from an organization that collaborates or funds a tobacco quitline, and/or a representative of the state department of health. All individuals will be adults (18 years and older) and able to speak English.
- Representative of the Healthcare Sector
- Representative of the healthcare sector will include any adult who works in healthcare, including but not limited to physicians, healthcare administrative leaders/managers, nurses, advanced practice providers. All individuals will be adults (18 years and older) and able to speak English.
Who cannot join
- Not applicable as our focus on quitline clients and representatives (adults) of the quitline community or the healthcare sector.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
UT MD Anderson
Houston, Texas, 77030
Lisa Lowenstein, PHD, 713-792-5807, lmlowenstein@mdanderson.org
Lisa Lowenstein, PHD
About this study
The goal of this research study is to compare two different ways to increase lung cancer screening rates for tobacco quitline clients.
Read the detailed description
Primary Objective/Aim:
Aim 1. Compare two dissemination strategies that vary in intensity on demand for LCS. We hypothesize that there will be a higher demand for LCS in the high-touch strategy arm compared to the low-touch strategy arm, as demonstrated by self-reported LCS completion, as well as scheduling a visit with a health care provider to discuss LCS.
Secondary Objectives/Aim:
Aim 2. Evaluate the impact on reach of the high-touch and low-touch strategies to disseminate LCS educational materials (i.e., view of the decision aid or participation in a decision coaching visit). We expect that disseminating the LCS educational materials through the high-touch strategy will result in higher reach than delivering the LCS educational materials through the low-touch strategy.
Aim 3. Evaluate the financial sustainability and cost-effectiveness of the two approaches of disseminating LCS educational materials. We expect that the high-touch strategy will require a greater financial commitment and stronger partnerships between quitline service providers, state department of health, and health care systems, it will be a cost-effective dissemination strategy compared to the low-touch strategy (emailing/texting).
- Conditions
- Lung Cancer
- Being tested
- High-touch strategy
- Keywords
- Tobacco
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High-touch strategyBehavioural
Participants will receive the LCS educational materials, decision coaching call for the SDM visit, and navigation for LCS.
| Study group | Role | What they receive |
|---|---|---|
| CMP: Comparator - Low-Touch Strategy (Usual Practice): LCS Educational Resources | Experimental | Investigators will use a parallel randomized controlled trial to compare a high-touch strategy (emailing/texting + decision coaching + navigation) to a low-touch strategy (emailing/texting) to distribute evidence based LCS educational resources to increase awareness and demand for LCS among quitline clients. Receives: Behavioral: High-touch strategy |
| INT: Intervention - High-Touch Strategy: LCS Educational Resources, Decision Coaching, Navigation | Experimental | Investigators will use a parallel randomized controlled trial to compare a high-touch strategy (emailing/texting + decision coaching + navigation) to a low-touch strategy (emailing/texting) to distribute evidence based LCS educational resources to increase awareness and demand for LCS among quitline clients. Receives: Behavioral: High-touch strategy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2026
- Study start1 Jan 2027 (estimated)
- Primary completion30 Jun 2032 (estimated)
- Study completion30 Jun 2034 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 650 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lisa Lowenstein, PHD, Principal investigator, UT MD Anderson
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07720141
- Sponsor's protocol ID
- 2026-0714
- Other IDs
- NCI-2026-05496
- Status last verified
- Jul 2026
- First submitted
- 17 Jul 2026
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dissemination Of Lung Cancer Screening Education Through Tobacco Quitlines
- ClinicalTrials.gov ID
- NCT07720141
- Acronym / sponsor ID
- 2026-0714
- Conditions
- Lung Cancer
- Keywords
- Tobacco
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 650 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 1 Jan 2027 (estimated)
- Primary completion
- 30 Jun 2032 (estimated)
- Study completion
- 30 Jun 2034 (estimated)
- First posted
- 22 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this research study is to compare two different ways to increase lung cancer screening rates for tobacco quitline clients.
Detailed description
Primary Objective/Aim:
Aim 1. Compare two dissemination strategies that vary in intensity on demand for LCS. We hypothesize that there will be a higher demand for LCS in the high-touch strategy arm compared to the low-touch strategy arm, as demonstrated by self-reported LCS completion, as well as scheduling a visit with a health care provider to discuss LCS.
Secondary Objectives/Aim:
Aim 2. Evaluate the impact on reach of the high-touch and low-touch strategies to disseminate LCS educational materials (i.e., view of the decision aid or participation in a decision coaching visit). We expect that disseminating the LCS educational materials through the high-touch strategy will result in higher reach than delivering the LCS educational materials through the low-touch strategy.
Aim 3. Evaluate the financial sustainability and cost-effectiveness of the two approaches of disseminating LCS educational materials. We expect that the high-touch strategy will require a greater financial commitment and stronger partnerships between quitline service providers, state department of health, and health care systems, it will be a cost-effective dissemination strategy compared to the low-touch strategy (emailing/texting).
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CMP: Comparator - Low-Touch Strategy (Usual Practice): LCS Educational Resources | Experimental | Behavioral: High-touch strategyInvestigators will use a parallel randomized controlled trial to compare a high-touch strategy (emailing/texting + decision coaching + navigation) to a low-touch strategy (emailing/texting) to distribute evidence based LCS educational resources to increase awareness and demand for LCS among quitline clients. |
| INT: Intervention - High-Touch Strategy: LCS Educational Resources, Decision Coaching, Navigation | Experimental | Behavioral: High-touch strategyInvestigators will use a parallel randomized controlled trial to compare a high-touch strategy (emailing/texting + decision coaching + navigation) to a low-touch strategy (emailing/texting) to distribute evidence based LCS educational resources to increase awareness and demand for LCS among quitline clients. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Quitline Client
- Quitline client participants must meet the criteria for LCS with regards to age (50 to 80 years) and smoking history (20+ pack-years). This project will not re-confirm quitline client participant eligibility for screening. Tobacco treatment specialists will elicit study interest from only eligible quitline clients.
- Representative of the Quitline Community
- Representative of the Quitline Community will include any employee of the quitline service provider, representative from an organization that collaborates or funds a tobacco quitline, and/or a representative of the state department of health. All individuals will be adults (18 years and older) and able to speak English.
- Representative of the Healthcare Sector
Key exclusion criteria (1 listed)
- Not applicable as our focus on quitline clients and representatives (adults) of the quitline community or the healthcare sector.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High-touch strategyParticipants will receive the LCS educational materials, decision coaching call for the SDM visit, and navigation for LCS. | Behavioural | CMP: Comparator - Low-Touch Strategy (Usual Practice): LCS Educational Resources, INT: Intervention - High-Touch Strategy: LCS Educational Resources, Decision Coaching, Navigation |
Primary outcome
Safety and Adverse Events (AEs)
Time frame: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
- UT MD Anderson WebsiteLink provided by the sponsor.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lisa Lowenstein, PHD principal investigator
UT MD Anderson
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High-touch strategy in people with Lung Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lisa Lowenstein, PHD ((713) 792-5807, lmlowenstein@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Adverse Events (AEs) (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.